149057-19-2 Usage
Description
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID, also known as 4-((Benzyloxy)carbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid, is a chemical compound that serves as a crucial intermediate in the synthesis of various pharmaceutical agents. It is characterized by its unique molecular structure, which includes a benzyloxycarbonyl group at the 4-position and a tert-butoxycarbonyl group at the 1-position, attached to a piperazine-2-carboxylic acid backbone. This structure endows it with specific reactivity and functional group compatibility, making it a valuable building block in the development of novel therapeutics.
Uses
Used in Pharmaceutical Industry:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a key intermediate for the synthesis of N-aryl piperazines. These N-aryl piperazines are being explored as potential CXCR4 antagonists and antivirals, which can have significant implications in the treatment of various diseases and conditions. The compound's unique structure allows for the development of new drugs with improved efficacy, selectivity, and reduced side effects.
Used in Antiviral Applications:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a precursor in the development of new antiviral agents. The synthesized N-aryl piperazines can potentially inhibit viral replication and entry into host cells, providing a novel approach to combat viral infections. This application is particularly relevant in the context of emerging and re-emerging viral diseases, where there is an ongoing need for new and effective antiviral therapies.
Used in Cancer Research:
In addition to its role in antiviral drug development, N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is also utilized in the synthesis of compounds with potential applications in cancer research. The resulting N-aryl piperazines may exhibit anti-cancer properties by targeting specific cellular pathways and receptors, thereby contributing to the development of novel cancer therapeutics.
Used in Drug Delivery Systems:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID can be employed in the design and development of drug delivery systems, particularly for the targeted delivery of CXCR4 antagonists and antivirals. By incorporating this compound into the design of drug carriers, researchers can potentially improve the bioavailability, stability, and targeted delivery of these therapeutic agents, leading to enhanced treatment outcomes and reduced side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 149057-19-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,0,5 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 149057-19:
(8*1)+(7*4)+(6*9)+(5*0)+(4*5)+(3*7)+(2*1)+(1*9)=142
142 % 10 = 2
So 149057-19-2 is a valid CAS Registry Number.
149057-19-2Relevant articles and documents
SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY
-
Paragraph 00121, (2020/02/23)
Compounds and methods of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 are provided. The compounds are of formula (I), (II), and (IA), wherein R1-R7, X, X', Y, Y', Z, and n are defined herein, and the methods comprises administering therapeutically effective amounts of these compounds to the human.
SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
-
, (2017/05/27)
There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.
OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
-
Page/Page column 117-118, (2010/12/31)
Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.
